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Abstract: The progress in the discovery and validation of metabolite biomarkers for the detection of
colorectal cancer (CRC) has been hampered by the lack of reproducibility between study cohorts.
The majority of discovery-phase biomarker studies have used patient blood samples to identify
disease-related metabolites, but this pre-validation phase is confounded by non-specific disease
influences on the metabolome. We therefore propose that metabolite biomarker discovery would
have greater success and higher reproducibility for CRC if the discovery phase was conducted in
tumor tissues, to find metabolites that have higher specificity to the metabolic consequences of the
disease, that are then validated in blood samples. This would thereby eliminate any non-tumor
and/or body response effects to the disease. In this study, we performed comprehensive untargeted
metabolomics analyses on normal (adjacent) colon and tumor tissues from CRC patients, revealing
tumor tissue-specific biomarkers (n = 39/group). We identified 28 highly discriminatory tumor tissue
metabolite biomarkers of CRC by orthogonal partial least-squares discriminant analysis (OPLS-DA)
and univariate analyses (VIP > 1.5, p < 0.05). A stepwise selection procedure was used to identify nine
metabolites that were the most predictive of CRC with areas under the curve (AUCs) of >0.96, using
various models. We further identified five biomarkers that were specific to the anatomic location of
tumors in the colon (n = 236). The combination of these five metabolites (S-adenosyl-L-homocysteine,
formylmethionine, fucose 1-phosphate, lactate, and phenylalanine) demonstrated high differentiative
capability for left- and right-sided colon cancers at stage I by internal cross-validation (AUC = 0.804,
95% confidence interval, CI 0.670–0.940). This study thus revealed nine discriminatory biomarkers of
CRC that are now poised for external validation in a future independent cohort of samples. We also
discovered a discrete metabolic signature to determine the anatomic location of the tumor at the
earliest stage, thus potentially providing clinicians a means to identify individuals that could be
triaged for additional screening regimens.
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1. Introduction
Colorectal cancer (CRC) is the second most common cause for cancer deaths worldwide, with
an annual mortality of 862,000 [1]. The survival rate for CRC patients is dependent on American
Joint Committee on Cancer (AJCC) stage, where longer survival is seen in those with earlier stage
tumors [2]. Therefore, it is of the utmost importance to identify lesions at an early stage so that patients
can receive appropriate treatment expeditiously. In the U.S., screening is currently recommended
for those aged >50 years, however, the American Cancer Society has recommended lowering this
age to 45, due to the recent increase in advanced-stage early-onset CRC cases before the age of 50 [3].
Current screening methods utilized globally include: fecal occult blood tests (FOBTs) (which include
fecal immunochemical test (FIT) or guaiac FOBT), stool DNA testing (FIT-DNA), sigmoidoscopy,
or standard colonoscopy. Patients that follow the recommended screening guidelines have a lowered
risk of death from CRC, however, there are barriers to screening, and <50% of individuals are
up-to-date with the recommendations. Some of these self-reported barriers include fear or worry of the
procedure, financial hardship, and logistical challenges such as transportation to medical providers [4].
Therefore, the utilization of alternative, less-invasive screening methods such as blood-based biomarker
tests would alleviate some of these barriers and identify those that may require further screening
or treatment.
A number of studies have attempted to use untargeted metabolomics to identify serum, plasma
and urinary metabolite biomarkers for CRC, with the ultimate aim being to develop a blood or
urine-based diagnostic test for screening [5,6]. However, these studies have not resulted in identifying
a panel of biomarkers that can be reproducibly validated between laboratories or sample cohorts.
Levels of some of the biomarkers have even been contradictory between studies; for example, alanine
was demonstrated to be increased in urine and serum in two studies [7,8], but it was reported to be
decreased in serum in another study [9]. This problem of reproducibility for biomarker discovery
is not only contained within CRC studies, but throughout the field of biomarker discovery using
metabolomics. In fact, the only clinical application of a blood-based clinical biomarker identified
by metabolomics is trimethylamine-N-oxide (TMAO). TMAO is a metabolite co-metabolized from
gut bacteria, and it can be measured in blood or urine. It has been linked to the development of
atherosclerosis and heart disease complications [10,11]. The lack of clinical applicability stems from
lack of study reproducibility. This is because of the difficulty in controlling physiological confounding
variables, such as body mass index (BMI), age, gender, and also differences in sample collection and
preparation, analytical instrumentation, and data analysis, which have been carried out in biofluids.
However, a major problem often discussed, but not addressed, is confounding non-tumor related
metabolites that are derived from the diet (fasting vs. fed, type of food), or are related to the effects
of circadian rhythm, exercise, and possible co-morbidities. Also, a large dilution effect can occur
to the tumor-originating metabolites once they enter the circulatory system, due to the larger pool
of non-tumor originating metabolites at higher concentrations in the blood. It may therefore be
difficult to find predictive metabolites from blood without ascertaining their levels in the tumors first.
Therefore, looking at the localized tumor-specific metabolites first, then extrapolating to measure the
same metabolites in blood or urine from CRC patients, would result in a higher likelihood of finding
specific and functional clinical biomarkers.
Limited studies have investigated the anatomic differences in the colon that could affect the
metabolism of the primary tumor [12,13]. Within the colon, tumors can form in different anatomic
regions. Lesions that develop on the proximal side of the colon (cecum, ascending colon and hepatic
flexure) are defined as right-sided colon cancers (RCCs), and those that develop on the distal side of the
colon (splenic flexure, descending, sigmoid and rectosigmoid) are left-sided colon cancers (LCCs) [14].
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Mounting evidence from epidemiologic studies have shown that clinical outcomes differ for patients
with RCCs compared with LCCs [15,16]. A recent meta-analysis comprising 66 studies and more than
1.4 million patients demonstrated that patients with RCC have worse overall prognosis than those with
LCC, even after stage matching [6]. Moreover, having a tumor originating in the left side of the colon
was associated with a 19% reduced risk of death from the disease [17]. Therefore, identifying anatomic
location-specific metabolite biomarkers could help indicate whether an individual may have the disease
and direct colonoscopy screening protocols to diagnose the patient. From a clinical perspective, RCC is
difficult to diagnose early, as patients do not present with symptoms such as rectal bleeding or anemia
until later stages, and the survival rate decreases as stage of diagnosis increases. Therefore, it reinforces
the need to find molecular biomarkers for early diagnosis. Previous in vitro metabolomics studies have
observed differences in the cholesterol biosynthesis pathway when comparing cell lines originating
from patients with RCC (HCT 116) and LCC (DLD-1), treated with calcitriol [18]. The results
suggested separate mechanisms of tumorigenesis for RCC and LCC. In addition, plasma metabolomics
analysis from RCC and LCC in CRC patients recently reported six potential biomarkers (anserine,
trimethylamine N-oxide, arginine, gamma-glutamyl-gamma-aminobutyraldehyde, indoxyl sulfate,
and pyridoxal 5′-phosphate), however these, again, suffer from the issue of plasma biomarker discovery
and subsequent validation [19].
In this study, a retrospective metabolomics data analysis was conducted on colon tissues (healthy
tissue and tumor) from CRC patients, to identify the tissue-specific biomarkers of CRC. An additional
focus was to examine the influence of anatomic location of the primary tumors. Initially, an untargeted
metabolomics data analysis was performed on normal colon tissues (n = 39) and primary colon
tumor tissues (n = 39, stage I–III), collected from CRC patients to discover tissue-specific metabolic
signatures. Then, comparative analyses were applied on a large cohort of RCC and LCC patients
(n = 236), to further find potential anatomic location-specific metabolic biomarkers.
2. Results
2.1. Metabolic Differences between Colon Cancer and Normal Controls
Untargeted metabolomics were initially performed on normal adjacent colon (n = 39) and primary
colon tumor tissues (n = 39, stage I–III), collected from CRC patients. The rationale for this analysis
was to identify metabolites that were dysregulated with respect to tumor tissues. Detailed information
on the clinical cohort is shown in Table S1. The data generated was subjected to principal components
analysis (PCA) and demonstrated a high level of analytical reproducibility, as revealed by the tight
clustering of QC samples (Figure S1). A supervised multivariate method using orthogonal partial
least-squares discriminant analysis (OPLS-DA) was subsequently applied to reveal global differences
in the metabolome between normal and tumor tissues. The OPLS-DA model revealed an excellent
separation of samples that were classified as either normal or tumor (R2Y = 0.96, Q2 = 0.77) (Figure 1a).
Permutation tests were carried out by comparing the goodness of fit (R2 and Q2) of the OPLS-DA
models with the goodness of fit of 200 Y-permutated models and demonstrated the validity of our
constructed supervised model (Q2 intercept −0.08) (Figure S2). Univariate analyses by Wilcoxon
Mann–Whitney U test with false discovery rate (FDR) adjustment was also applied to find significantly
altered features between normal colon and colon tumor tissues. Twenty-eight metabolites were
identified that met with three criteria, a variable importance projection (VIP) >1.5 from the OPLS-DA
analysis, with a FDR-corrected p-value < 0.05, and fold change > 1.2 or < 0.8 from univariate analysis,
and are considered as potential metabolic biomarkers for CRC (Figure 1b,c). Of note, large metabolic
differences were shown to exist between normal and tumor tissues; there, a stringent threshold of
VIP >1.5 was applied to identify the most discriminatory metabolites, to use as potential clinical
biomarkers. The metabolomics standards initiative (MSI) identification level and detailed information
on the 28 tissue metabolites are shown in Table S2.
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Figure 1. Metabolic differences in colon cancer revealed by untargeted metabolome profiling. (a) 
Orthogonal partial least-squares discriminant analysis (OPLS-DA) scores plot assessing variance of 
features between normal colon and colon tumors (n = 39/group). Dotted circle in the plot indicates the 
95% confidence interval. For the OPLS-DA model, R2Y = 0.96, Q2 = 0.77. (b) The 28 identified 
metabolites from OPLS-DA analysis ranked by variable importance in the projection (VIP) values. (c) 
Heatmap showing significantly different expression levels of metabolites in cancer (vs. normal, n = 
39) colon tissues (n = 39). Scale is z-score. (d) Receiver operating curve (ROC) plots of predictive 
models, based on 28 metabolic biomarkers, using partial least-squares (PLS), random forest (RF), and 
support vector machine (SVM), respectively. 
2.2. Distinct Metabolomic Signatures Associated with Anatomic Location 
To investigate the influence of tumor location on the metabolome, we analyzed a larger number 
of colon tumor tissues from CRC patients (n = 197), which included the 39 tumor samples analyzed 
in the previous section. The detailed information on this clinical cohort is shown in Table S3. The 
PCA conducted on the patient samples and QCs showed tightly clustered QC samples (Figure S5). 
OPLS-DA models were used to examine tumor stage-specific differences between RCCs from LCCs. 
In addition, the stage II model was constructed by taking tumor size into account; since differences 
in tumor size were observed between RCC and LCC, larger tumors may exhibit areas of hypoxia 
which could affect metabolism (Table S3). As the OPLS-DA plots demonstrate in Figure 2, distinct 
metabolic profiles were observed between RCC and LCC patients when stratified by stage. 
Meanwhile, permutation tests demonstrated that all three OPLS-DA models were well fitted, as the 
Figure 1. Metabolic differences in colon cancer revealed by untargeted metabolome profiling.
(a) Orthogonal partial least-squares discriminant analysis (OPLS-DA) scores plot assessing variance of
features between normal colon and colon tumors (n = 39/group). Dotted circle in the plot indicates
the 95% confidence interval. For the OPLS-DA model, R2Y = 0.96, Q2 = 0.77. (b) The 28 identified
etabolites fro OPLS-DA analysis ranked by variable importance in the projection (VIP) values.
(c) Heatmap showing significantly different expression levels of metabolites in cancer (vs. normal,
n = 39) colon tissues (n = 39). Scale is z-score. (d) Receiver operating curve (ROC) plots of predictive
odels, based on 28 metabolic biomarkers, using partial least-squares (PLS), random forest (RF),
and support vector machine (SVM), respectively.
To fur her evaluate the predictive performance of the 28 potential biomarkers, three different
models were used with a seven-fold cross validation strategy; partial least-squares (PLS), random
forest (RF), and support vector machine (SVM) models. These models were constructed, and the
area under the curve (AUC) from the receiver operating characteristic (ROC) curves were computed.
Notably, all three models exhibited excellent discriminative performance for CRC based on the
28 biomarkers (Figure 1d). The AUC values were 0.96 (95% confidence interval, CI 0.91–1.00), 0.96 (95%
confidence interval, CI 0.92–1.00), and 0.95 (95% confidence interval, CI 0.90–1.00), for PLS, RF, and SVM,
respectively. Notably, creatinine [7,8], taurine [20], lactate [8,21], glutamate [19], CDP-choline [20],
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and glycerol-3-phosphate [22] have been previously reported as correlated to colon cancer from the
analysis of urine, serum, or plasma samples from colon cancer patients.
Given that a biomarker panel of 28 metabolites would be challenging to use for clinical application,
we carried out stepwise selection on the 28 potential metabolic biomarkers to identify a discrete number
that are predictive. The 28 metabolites were sorted according to their VIP values, then, the backward
stepwise regression procedure was performed by removing the metabolite with the smallest VIP in
each step. In each step, a PLS prediction model was constructed using the remaining metabolites.
The bootstrap method was used to sample the dataset [23]. In brief, 63% randomly selected patients
from the dataset were selected as discovery data to build the prediction model, and the remaining
37% patients were used as validation data. This random sampling with model construction and
validation procedure was repeated 1000 times, and the AUCs were calculated and recorded (Figure
S3a). The combination of the top nine metabolites ranked by VIP values (Table S2; taurine, glutamate,
CDP-choline, fructose 6-phosphate, hypoxanthine, phenylalanine, phosphoethanolamine, creatinine,
and GDP-glucose) was able to construct predictive models and had an excellent AUC value of 0.98
(95% confidence interval, CI 0.95–1.00), 0.97 (95% confidence interval, CI 0.93–1.00), and 0.96 (95%
confidence interval, CI 0.91–1.00) for RF, PLS, and SVM, respectively (Figure S3b). Of note, the top
nine metabolites resulted in the highest AUC value, and increasing the number of biomarkers did
not improve the AUC value. To validate the nine CRC metabolic markers, we further assessed their
predictive performance in another set of CRC tumor samples, using PLS, RF, and SVM models (Table
S1). The results demonstrated that all three models exhibited excellent discriminative performance for
CRC based on the nine biomarkers (Figure S4). The AUC values were 0.86 (95% confidence interval, CI
0.76–0.96), 0.93 (95% confidence interval, CI 0.88–0.99), and 0.91 (95% confidence interval, CI 0.84–0.98),
for PLS, RF, and SVM, respectively.
2.2. Distinct Metabolomic Signatures Associated with Anatomic Location
To investigate the influence of tumor location on the metabolome, we analyzed a larger number
of colon tumor tissues from CRC patients (n = 197), which included the 39 tumor samples analyzed in
the previous section. The detailed information on this clinical cohort is shown in Table S3. The PCA
conducted on the patient samples and QCs showed tightly clustered QC samples (Figure S5). OPLS-DA
models were used to examine tumor stage-specific differences between RCCs from LCCs. In addition,
the stage II model was constructed by taking tumor size into account; since differences in tumor size
were observed between RCC and LCC, larger tumors may exhibit areas of hypoxia which could affect
metabolism (Table S3). As the OPLS-DA plots demonstrate in Figure 2, distinct metabolic profiles were
observed between RCC and LCC patients when stratified by stage. Meanwhile, permutation tests
demonstrated that all three OPLS-DA models were well fitted, as the permutated R2 and Q2 values
were both smaller than the experimentally-derived values, meaning that the models are significant
and predictive (Figure S6a,c). Although separation between RCCs and LCCs was also seen visually
by integrating tumors across stages I–III, the statistical model was not validated by the permutation
test in which the permutated R2 value was larger when experimentally calculated (Figure S7). The Q2
value in the PLS model is often used to assess predictive ability and is calculated using a blindfolded
procedure, and a model with Q2 > 0 is regarded as having predictive relevance [24]. Among the
three OPLS-DA models, the resulting model from stage I tumors had the best predictive ability, with
a Q2 value of 0.45. The stage II model had a lower Q2 value of 0.23, and stage III has a Q2 value of
−120.27; the latter therefore showing poor predictive ability. The R2Y values, which are the fraction of
the variation of Y variables explained by the models, are 0.96, 0.87, and 0.91 for stage I, and stage II,
and stage III, respectively. The results indicate that the metabolomics profiles for stage I patients can
discriminate between those with early-stage RCC and LCC, indicating potential biomarkers for early
stage CRC by lesion location.
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2.3. Potential Metabolic Biomarkers for Early-Stage LCC and RCC
To identify metabolic biomarkers for early-stage (stage I) LCC and RCC, we next incorporated
normal controls into the biomarker discovery procedure. This was to ensure that the markers were not
only markers of tissue location, but were also markers of cancer in these different regions. The criteria
for the selection of potential metabolic biomarkers were set as follows: (1) VIP value (OPLS-DA) > 1.0;
(2) p value (LCCs vs. RCCs) < 0.05; (3) p value (normal colon tissues from left-side vs. normal colon
tissues from right-side) >0.05; (4) p value (normal colon tissues from left-side vs. LCCs) < 0.05 or p
value (normal colon tissues from right-side vs. RCCs) < 0.05. The VIP criteria (>1.0) was different
from above one (>1.5), ascribing to a large difference between normal colon and tumor, and relative
smaller difference between RCC and LCC. A total of five metabolites met with above-mentioned
criteria and were selected as potential metabolic biomarkers for LCCs and RCCs. These metabolites are
S-adenosyl-L-homocysteine (SAH), formylmethionine, fucose 1-phosphate, lactate, and phenylalanine.
The detailed information is displayed in Table 1.
Table 1. Potential metabolic biomarkers discriminate LCCs from RCCs at stage I.
Metabolite m/z RT FC a VIP b p c p d p e p f
SAH 385.1282 363.2 0.29 1.8 0.028 0.001 0.026 N.S.
Formylmethionine 176.0393 188.9 0.64 1.9 0.010 <0.001 0.033 N.S.
Fucose 1-phosphate 243.0285 438.0 0.38 1.3 0.026 0.001 0.010 N.S.
Lactate 89.0233 218.2 0.75 2.1 0.008 0.046 N.S. N.S.
Phenylalanine 207.1130 252.0 0.53 2.3 0.003 0.019 N.S. N.S.
a FC: median value in RCCs divided by median value in LCCs. b VIP: variable importance in the projection
from OPLS-DA models. c p: Wilcoxon Mann–Whitney U test, LCCs vs. RCCs, FDR-corrected. d p: Wilcoxon
Mann–Whitney U test, left-sided normal colon vs. LCCs, FDR-corrected. e p: Wilcoxon Mann–Whitney U test,
right-sided normal colon vs. RCCs, FDR-corrected. f p: Wilcoxon Mann–Whitney U test, left-sided normal colon vs.
right-sided normal colon, FDR-corrected.
As shown in Figure 3a, three metabolites (SAH, formylmethionine, and fucose 1-phosphate)
were consistently upregulated in tumor tissues compared to normal tissues from the same side of the
colon, and could be considered as potential biomarker candidates of stage I CRC for either LCC or
RCC. However, two additional metabolites were only increased in LCCs, lactate and phenylalanine.
Of note, no difference (p > 0.05) was observed between left-sided normal colon and right-sided normal
colon for the five discovered potential biomarkers (Table 1). We further developed a random forest
model with the five potential biomarkers, to investigate the predictive performance in determining
whether a tumor is stage I LCC or RCC. The combination of these five metabolites demonstrated
a good differentiative capability (Figure 3b). The AUC value of the five metabolites combined is
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0.804 (95% confidence interval, CI 0.670−0.940), with a sensitivity of 86.4% and specificity of 68.0%
for stage I LCC. It is worthy to note that these five metabolites are also general potential biomarkers
for colon cancer, regardless of stage or anatomic location, as we demonstrated in our comparison of
normal colon to colon tumor tissues. However, as can be seen here, some caution may be needed
when delving into specific subgroups such as stage I RCC, as the markers may have lower specificity.
Therefore, we performed an additional examination. A further stratification by tumor stages (stage I,
stage II, and stage III) and anatomic location were conducted on the five anatomic-specific metabolic
biomarkers. Among them, SAH, formylmethionine, and fucose 1-phosphate were up-regulated in
patients with LCC and RCC across all stages, (p < 0.05) (Figure 4). Lactate was increased only in LCCs
at stage I, and it was not changed in LCCs at stages II and III, compared with normal control tissues
from the left side of the colon. However, lactate was up-regulated in stage III RCCs compared to
normal right-sided colon tissues. A similar difference was seen for the essential aromatic amino acid
phenylalanine; this metabolite was only increased in LCCs at stage I, and not changed in RCCs at any
stages compared to normal tissues.
Metabolites 2020, 10, x FOR PEER REVIEW 7 of 14 
 
a FC: median value in RCCs divided by median value in LCCs. b VIP: variable importance in the 
projection from OPLS-DA models. c p: Wilcoxon Mann–Whitney U test, LCCs vs. RCCs, FDR-
corrected. d p: Wilcoxon Mann–Whitney U test, left-sided normal colon vs. LCCs, FDR-corrected. e p: 
Wilcoxon Mann–Whitney U test, right-sided normal colon vs. RCCs, FDR-corrected. f p: Wilcoxon 
Mann–Whitney U test, left-sided normal colon vs. right-sided normal colon, FDR-corrected. 
As shown in Figure 3a, three metabolites (SAH, formylmethionine, and fucose 1-phosphate) 
were consistently upregulated in tumor tissues compared to normal tissues from the same side of the 
colon, and could be considered as potential biomarker candidates of stage I CRC for either LCC or 
RCC. However, two additional metabolites were only increased in LCCs, lactate and phenylalanine. 
Of note, no difference (p > 0.05) was observed between left-sided normal colon and right-sided normal 
colon for the five discovered potential biomarkers (Table 1). We further developed a random forest 
model with the five potential biomarkers, to investigate the predictive performance in determining 
whether a tumor is stage I LCC or RCC. The combination of these five metabolites demonstrated a 
good differentiative capability (Figure 3b). The AUC value of the five metabolites combined is 0.804 
(95% confidence interval, CI 0.670−0.940), with a sensitivity of 86.4% and specificity of 68.0% for stage 
I LCC. It is worthy to note that these five metabolites are also general potential biomarkers for colon 
cancer, regardless of stage or anatomic location, as we demonstrated in our comparison of normal 
colon to colon tumor tissues. However, as can be seen here, some caution may be needed when 
delving into specific subgroups such as stage I RCC, as the markers may have lower specificity. 
Therefore, we performed an additional examination. A further stratification by tumor stages (stage I, 
stage II, and stage III) and anatomic location were conducted on the five anatomic-specific metabolic 
biomarkers. Among them, SAH, formylmethionine, and fucose 1-phosphate were up-regulated in 
patients with LCC and RCC across all stages, (p < 0.05) (Figure 4). Lactate was increased only in LCCs 
at stage I, and it was not changed in LCCs at stages II and III, compared with normal control tissues 
from the left side of the colon. However, lactate was up-regulated in stage III RCCs compared to 
normal right-sided colon tissues. A similar difference was seen for the essential aromatic amino acid 
phenylalanine; this metabolite was only increased in LCCs at stage I, and not changed in RCCs at any 
stages compared to normal tissues. 
 
Figure 3. Potential metabolic biomarkers for stage I LCC and RCC. (a) Abundance of
S-adenosylhomocysteine (SAH), formylmethionine, fucose 1-phosphate, lactate, and phenylalanine in
left-sided normal colon (Normal Left, n = 17), left-sided colon cancer (LCC, n = 25), right-sided normal
colon (Normal Right, n= 22), and right-sided colon cancer (RCC, n= 22). Nonparametric Kruskal–Wallis
rank sum test with pairwise Wilcoxon Mann–Whitney U test, p values adjusted for false discovery rates
(FDR) (Benjamini–Hochberg). * p < 0.05, ** p < 0.01, *** p < 0.001, NS. = not significant. (b) ROC curve
plot of predictive model, based on five metabolic biomarkers using random forest (RF), differentiating
LCC from RCC.
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3. Discussion
Altered metabolism is a significant feature of CRC, and dysregulated metabolites are associated
with colon cancer development, prognosis, and recurrence [9,25–27]. A number of studies have used
untargeted metabolomics to identify metabolite biomarkers for CRC from various accessible biofluids
collected from patients, such as plasma, serum, and urine [5,6]. The most com only identified
metabolite biomarkers for CRC from these studies were amino acids (alanine, glutamine, glutamate
etc.), carbohydrates (lactate, pyruvate etc.), and fatty acids (butyrate, propionate etc.) Generally,
a pa el of metabolite bio arkers dem nstrated better diagnostic performa ce than a single biom rker.
However, these studies have been hampered by lack of re roducibility, and in some cases, results
are contradictory. In our previous work, an untargeted metabolomics analysis was performed on
normal colon and primary col n tumor tissues collected from a larg cohort of CRC p tients, to identify
sex-associated differ ces in colon ancer metabolism [13]. In this study, we carried out a retrospective
metabolomics data analysis to identify tissue-specific bi markers of CRC from th s cohort. Our first
aim was to identify highly pecific CRC biomarkers through the examinati n of normal colon and
primary colon tumor tissues. I total, we identified 28 metabolites which demonstrated excellent
discriminative performanc by machine learning based PLS, SVM and RF models. We then used a
backwar stepwise r gres ion method to identify the nine most discriminatory metabolites that could
be used as bio arker panel for testing in the blood r urin from CRC patients.
Of note, four out of nine metabolites we identified are perfectly consistent with the results from
various metabolomics studies using biofluid or tissue samples. Taurine and glutamate, which are with
the highest VIP values in the OPLS-DA model, are consistently upregulated in different CRC study
cohorts with tumor tissue derived from tissue, plasma, and serum [20,28–30]. Additionally, our study
identified CDP-choline, a dispensable intermediate for the synthesis of structural phospholipids of cell
membranes, and had a VIP of 2.22. This metabolite is also increased in plasma samples from other
CRC studies [20]. The down-regulation of creatinine which we identified, is in accordance with other
studies using urine, plasma, and serum samples [8,20,31]. Given that these potential biomarkers were
readily measured and validated in biofluid samples, it is highly plausible that the metabolites our study
identified is of potential value to develop clinically applicable markers for CRC diagnosis with further
validation in different bio-fluid sample cohorts. In addition, further studies that include controls from
other intestinal diseases such as colitis, Crohn’s disease, diverticulitis, and also from other types of
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tumor, are required to demonstrate the specificity of metabolite biomarkers for colorectal tumorigenesis.
Moreover, it is highly recommended to investigate the specificity of metabolite biomarkers in a newly
collected biobank, since one limitation of the current study might be that metabolite degradation could
happen during long-term storage.
Since anatomic tumor location is associated with symptoms, screening efficacy, and patient
survival, we carried out metabolomics analysis, stratified by AJCC stage, on a large cohort of patients
with either RCC or LCC, to identify metabolic biomarkers that differentiate tumors based on location.
We identified five metabolites (SAH, formylmethionine, fucose 1-phosphate, lactate, and phenylalanine)
which are specific for stage I LCC. This combination of these five biomarkers demonstrated a good
predictive power for differentiating between stage I RCCs and LCCs with AUC value 0.804 (95%
confidence interval, CI 0.670–0.940). Importantly, these metabolites were specific for cancer tissue,
and were not different when comparing healthy right-sided colon and left-sided colon.
Patients with RCC have worse prognosis than those with LCC, and RCC is less likely to be
diagnosed at an early stage. Thus, the clinical applicability of the panel of five biomarkers identified
in our study may prove to be useful for medical providers. To explore the clinical application of the
five metabolites, their abundance level and limits of detection in blood or urine samples need to be
further examined, because of the dilution effect in biofluids. Furthermore, validation in independent
cohorts with biofluid samples, comparing patients with RCC and LCC at early stages, is required.
Finally, future survival analyses could be valuable, to reveal the association between the five metabolite
biomarkers identified in our study and the prognosis of patients with RCC or LCC.
In conclusion, our data has revealed a biomarker panel of nine metabolites specific for CRC.
We also identified tumor location-specific biomarkers for stage I CRC with potential clinical implications.
Future studies examining the clinical utility of these biomarkers in biofluids for the non-invasive
screening of early stage colon cancer are underway.
4. Materials and Methods
4.1. Chemicals
Ammonium acetate and formic acid were purchased from Fisher Scientific (Morris Plains, NJ,
USA). Ammonium hydroxide was purchased from Honeywell (Muskegon, MI, USA). Water (H2O),
methanol (MeOH) and acetonitrile (ACN) were LC-MS grade and were purchased from Fisher Scientific
(Morris Plains, NJ, USA).
4.2. Sample Collection
Colon tumor and normal colon tissue (away from the tumor at the resection margin) were acquired
from surgical colectomy specimens and prospectively collected on 736 stage I–IV CRC patients in
the period 1991–2001 at Memorial Sloan-Kettering Cancer Center (MSKCC, New York, NY, USA).
Clinical data were recorded and updated retrospectively. Each sample was snap frozen in liquid nitrogen
and immediately stored at −80 ◦C. Pre-operative intravenous antibiotics (cefazolin/metronidazole,
clindamycin/gentamicin or ciprofloxacin/metronidazole) were administered within 60 min prior to
resection. All patients received a standard mechanical bowel preparation (polyethylene glycol (PEG)
solution) 24 h before scheduled surgery. For this study, samples were selected from patients that
were ≥55 years old, to reduce the confounding effects of estrogen signaling on metabolism before
menopause. All normal colon tissues were selected from stage I–IV CRC patients (n = 39), and tumor
tissue samples were selected from RCCs and LCCs stage I–III (n = 197). Stage IV tumor samples
were not included, as their metabolism may be affected by the presence of metastases in the liver or
other site, therefore we cannot rule out this confounder. Normal adjacent tissues were from stage I–IV
patients. Normal colon tissue samples were taken from stage IV patients, as their metabolic profiles
were not significantly different from the normal ones taken from stage I–III (Figure S8), and they were
markedly different from the tumor samples. The Yale University Institutional Review Board (IRB)
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determined that the study conducted in this publication was not considered to be Human Subjects
Research and did not require an IRB review (IRB/HSC# 1612018746).
4.3. Tissue Metabolite Extraction
First, 50 ± 1 mg of each tissue was homogenized using 500 µL of UPLC-grade H2O. A Cryolys
Evolution homogenizer (Bertin Corporation, Rockville, MD, USA) was used with 2 mL lysing tube
(Bertin Corporation) and 1.4 mm ceramic zirconium oxide beads (Bertin Corporation) to homogenize
the tissues. Each sample was processed six times for 20 s, at 6000 rpm with 5 s intervals. Dry ice
was used to keep the temperature <10 ◦C during homogenization. From the homogenized solution,
100 µL was taken and added to 1.5 mL polypropylene microcentrifuge tubes for subsequent metabolite
extraction. A volume of 400 µL ice cold MeOH:ACN (1:1, v/v) was added to each sample as the
extraction solvent. The samples were vortexed for 30 s, and sonicated for 10 min. To precipitate
proteins, the samples were incubated for 2 h at −20 ◦C, followed by centrifugation at 13,000 rpm
(15,000× g) and 4 ◦C for 15 min. The resulting supernatant was removed and evaporated to dryness for
12 h using a vacuum concentrator (Thermo Fisher Scientific, Waltham, MA, USA). The dry extracts were
then reconstituted in 100 µL of ACN:H2O (1:1, v/v), sonicated for 10 min, and centrifuged at 13,000 rpm
(15,000× g) and 4 ◦C for 15 min, to remove insoluble debris. The supernatant was transferred to UPLC
autosampler vials (Thermo Scientific, Waltham, MA, USA). A pooled quality control (QC) sample was
prepared by mixing 5 µL of extracted solution from each sample into a UPLC autosampler vial. All the
vials were capped and stored at −80 ◦C prior to UPLC-MS analysis.
4.4. UPLC-MS Analysis
Both hydrophilic interaction chromatography mass spectrometry (HILIC-MS) and reverse phase
liquid chromatography mass spectrometry (RPLC-MS) approaches were used for a comprehensive
analysis of the tissue metabolome. A UPLC system (H-Class ACQUITY, Waters Corporation, Milford,
MA, USA), coupled to a quadrupole time-of flight (QTOF) mass spectrometer (Xevo G2-XS QTOF,
Waters Corporation, Milford, MA, USA), was used for MS data acquisition. A Waters ACQUITY UPLC
BEH Amide column (particle size, 1.7 µm; 100 mm (length) × 2.1 mm (i.d.)) and Waters ACQUITY
UPLC BEH C18 column (particle size, 1.7 µm; 50 mm (length) × 2.1 mm (i.d.)) were used for the
UPLC-based separation of metabolites. The column temperature was kept at 25 ◦C for HILIC-MS
analysis and 30 ◦C for RPLC-MS analysis. The solvent flow rate was 0.5 mL/min, and the sample
injection volume was 1 µL. For HILIC-MS analysis, mobile phase A was 25 mM NH4OH and 25 mM
NH4OAc in water, while the mobile phase B was can, for both electrospray ionization (ESI), positive
and negative mode, respectively. The linear gradient was set as follows: 0~0.5 min: 95% B; 0.5~7 min:
95% B to 65% B; 7~8 min: 65% B to 40% B; 8~9 min: 40% B; 9~9.1 min: 40% B to 95% B; 9.1~12 min:
95% B. For RPLC-MS analysis, the mobile phases A was 0.1% formic acid in H2O, while the mobile
phases B was 0.1% formic acid in ACN, respectively, for both ESI+ and ESI−. The linear gradient was
set as follows: 0~1 min: 1% B; 1~8 min: 1% B to 100% B; 8~10 min: 100% B; 10~10.1 min: 100% B to
1% B; 10.1~12 min: 1% B. Pooled samples were analyzed every eight injections during the UPLC-MS
analysis to monitor the stability of the data acquisition, and used for subsequent data normalization.
QTOF scan data (300 ms/scan; mass scan range 50–1000 Da) were initially acquired for each
biological sample for metabolite quantification. Then, both DDA (data-dependent acquisition) data
(QTOF scan time: 50 ms/scan, MSMS scan time 50 ms/scan, collision energy 20 eV, top 5 most intense
ions were selected for fragmentation, exclude former target ions (4 s after 2 occurrences)) and MSE data
(low energy scan: 200 ms/scan, collision energy 6 eV; high energy scan: 100 ms/scan, collision energy
20 eV, mass scan range 25–1000 Da) were acquired for QC samples to enable metabolite identification.
ESI source parameters on the Xevo GS-XS QTOF were set as the following: capillary voltage 1.8 kV,
sampling cone 40 V, source temperature 50 ◦C, desolvation temperature 550 ◦C, cone gas flow 40 L/h,
desolvation gas flow 900 L/h.
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4.5. UPLC-MS Data Processing
The raw MS data (.raw) were converted to mzML files using ProteoWizard MSConvert (version
3.0.6150, www.proteowizard.sourceforge.net/). The parameters of min SNR and min peak spacing were
set as 0.1 for peak picking in ProteoWizard. The files were then processed in R (version 3.4.3), using the
XCMS package for feature detection, retention time correction, and alignment. The XCMS processing
parameters were optimized and set as follows: mass accuracy for peak detection = 25 ppm; peak width
c = (2, 30); snthresh = 6; bw = 10; mzwid = 0.015; minfrac = 0.5. The CAMERA package was used for
subsequent peak annotation. The resulting data were normalized using the support vector regression
algorithm in R, to remove an unwanted system error that occurred among intra- and inter-batches.
Initial metabolite identification was performed using the MetDNA algorithm. Metabolites were further
identified by matching retention time with an in-house metabolite standard library. In addition,
metabolite identification was carried out by matching accurate mass and experimental MS/MS data
against online databases (METLIN and HMDB).
4.6. Statistical Analysis
All statistical analyses were performed on the R platform (version 3.4.3). Orthogonal partial
least-squares discriminant analysis (OPLS-DA) was used to discover global metabolic changes
between colon cancer and healthy matched tissue controls, and also between right-sided colon
cancer (RCC) and left-sided colon cancer (LCC), based on R package “plsdepot”. The corresponding
variable importance in the projection (VIP values) was calculated in the OPLS-DA model.
Meanwhile, the Wilcoxon Mann–Whitney U test, with Benjamini–Hochberg-based false discovery rates
(FDR) adjust, was performed, using the R function “p.adjust” for differential analysis between colon
cancer and healthy controls. For multiple groups comparisons, the nonparametric Kruskal–Wallis
rank sum test was performed to determine the significance of each metabolite, and the relevant
false discovery rates (FDR) based on the p values were estimated in the context of multiple testing.
Internal cross validations of selected potential biomarkers were performed by using random forest (RF)
model, partial least-squares (PLS) model, and supported vector machine (SVM) model in R. To evaluate
the classification performance, the area under the receiver operating characteristic curve (AUC) value
and 95% confidence interval (CI) were computed, using the pROC package on the R platform.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/6/257/s1.
Figure S1: PCA scores plot on normal control, colon cancer, and QC samples. Figure S2: Validation plot obtained
from 200 permutation tests Figure S3: (a) AUC values of PLS prediction models with different number of metabolic
biomarkers. (b) ROC plots of predictive models based on 9 metabolic biomarkers using random forest (RF), partial
least-squares (PLS), and support vector machine (SVM), respectively. Figure S4: Stage stratified PCA score plots
on left-sided colon cancer (LCC), right-sided colon cancer (RCC), and QC samples. Figure S5: Validation plots
obtained from 200 permutation tests for (a) stage I LCC (n = 25) and stage I RCC (n = 22) (b) stage II LCC (n = 42)
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metabolic fingerprints of stages I–III LCC (n = 99) and stages I–III RCC (n = 98). (b) The validation plots obtained
from 200 permutation tests. Figure S7: (a) OPLS-DA plot for metabolic signatures of stages I–III LCC (n = 99) and
stages I–III RCC (n = 98). (b) Validation plots obtained from 200 permutation tests. Figure S8: PCA scores plot of
normal colon tissues from stage I–III patients and stage IV. Table S1. Demographics of colon cancer patients from
samples used for discovery of metabolic differences between colon cancer and normal controls. Table S2. List of
identified 28 potential metabolic biomarkers for colon cancer. Table S3. Demographics of colon cancer patients
from samples used for discovery of metabolic differences between RCC and LCC. Right-sided colon cancer = RCC,
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